Evidence map›Paper›PMID 31852738›Full record

ArticleThe Journal of biological chemistry2020

Cl

Min-Hwang Chang, Matthew R Brown, Yiran Liu, Vladimir G Gainullin, Peter C Harris, Michael F Romero, John C Lieske

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  3. Article
  4. Review
  5. 4-Phenylbutyric Acid Treatment Reduces Low-Molecular-Weight Proteinuria in aInternational journal of molecular sciences · 2024
    Article
  6. The Site and Type ofKidney international reports · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Making a Dent in Dent Disease.Function (Oxford, England) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Min-Hwang ChangDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; O'Brien Urology Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905. Electronic address: chang.minhwang@mayo.edu.
Matthew R BrownDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; Wayne State University, Detroit, Michigan 48202.
Yiran LiuDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; University of Michigan, Ann Arbor, Michigan 48109.
Vladimir G GainullinDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; Department of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota 55905.
Peter C HarrisDepartment of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; Department of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota 55905.
Michael F RomeroDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; O'Brien Urology Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; Department of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota 55905.
John C LieskeDepartment of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; O'Brien Urology Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905; Department of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota 55905.

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
VISUALIZATION AND PATHOPHYSIOLOGY OF RENAL STONE PRECURSOR LESIONSU54DK100227 · NIDDK · MAYO CLINIC ROCHESTER · PI LIESKE, JOHN C · 2013 to 2017
$6.3M
Mayo Clinic Summer Undergraduate Research in Nephrology & UrologyR25DK101405 · NIDDK · MAYO CLINIC ROCHESTER · PI MICHAEL F. ROMERO · 2014 to 2026
$1.6M
Facilitating personalized medicine of monogenic stone patients by genetic characterizationR21TR003174 · NCATS · MAYO CLINIC ROCHESTER · PI HARRIS, PETER C., LIESKE, JOHN C · 2020 to 2021
$437k
NCATS NIH HHS R21 TR003174NIDDK NIH HHS R25 DK101405NIDDK NIH HHS U54 DK083908NIDDK NIH HHS U54 DK100227
6 · The paper itself

Abstract

Dent disease 1 (DD1) is caused by mutations in the

Indexed as

Point MutationAnimalsCell LineChloride ChannelsChloridesEndosomesGenetic Diseases, X-LinkedHumansHydrogenIon TransportNephrolithiasisProtein TransportXenopusChloride ChannelsChloridesCLC-5 chloride channelHydrogenCLCN5Cl−/H+ exchanger ClC-5dent disease 1 (DD1)electrophysiologyepithelial cellion-sensitive electrodekidney disorderstoichiometrytransporterXenopus oocyte

Identifiers

PMID31852738
PMCPMC7008381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.